Sandoz, a Germany-based division of the Novartis group, has established a new product development center located in East Hanover, New Jersey.
Subscribe to our email newsletter
Sandoz said that the development in East Hanover is expected to focus on products that can generally be submitted as abbreviated new drug applications to the FDA for approval as generic alternatives to branded pharmaceutical products.
Further, the new development center is expected to be a key site for its US development of generic medicines.
Sandoz also said that the development center also hosts members of its Regulatory Affairs group.
Don DeGolyer, president of Sandoz, said: “We are pleased to introduce a new Sandoz development center on the Novartis East Hanover campus, a facility that is expected to enable us to further build on our internal development capability. This new center should enable us to capitalise on synergies within Novartis Pharmaceuticals, as well as benefit from talent here in New Jersey.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.